Personal Genome Diagnostics (PGDx) specializes in precision oncology by providing comprehensive genomic profiling (CGP) solutions that empower personalized cancer care. Their flagship products, PGDx elio™ tissue complete and PGDx elio plasma complete, offer rapid and actionable insights for advanced cancer patients through both tissue and liquid biopsy methods. The PGDx elio tissue complete test is notable for being the first FDA-cleared and CE-IVD marked comprehensive kitted solution, capable of analyzing over 500 solid tumor-related genes with a clinical success rate exceeding 92%. This test identifies various genetic alterations, including somatic mutations, tumor mutation burden (TMB), and microsatellite instability (MSI), enabling healthcare providers to make informed treatment decisions.

PGDx's innovative approach is further enhanced by their proprietary bioinformatics platform, which ensures high sensitivity and specificity in genomic analysis. The automated bioinformatics system streamlines the workflow from sample preparation to result reporting, allowing labs to maintain control over their data and specimens. With a focus on decentralizing CGP, PGDx aims to make genomic testing accessible to laboratories worldwide, facilitating timely and reliable insights that can significantly impact patient care. Their commitment to advancing cancer research and diagnostics is evident in their continuous optimization of their product offerings and the integration of new biomarkers as they emerge.

United States

Personal Genome Diagnostics (PGDx) is empowering the fight against cancer by unlocking actionable information from the genome. We are committed to developing a portfolio of regulated tissue-based and liquid biopsy genomic products for laboratories worldwide.Our expertise in advanced cancer genome analysis ranges from sample preparation and sequencing to data interpretation and analysis. We specialize in high-throughput next-generation sequencing, proprietary algorithms to identify alterations in complex cancer genomes and have developed novel technologies for non-invasive approaches in cancer.

Personal Genome Diagnostics - PDGx

Company Details